Literature DB >> 31241315

Reversible Immuno-Infrared Sensor for the Detection of Alzheimer's Disease Related Biomarkers.

Brian Budde1,2, Jonas Schartner1,2, Lars Tönges3,2, Carsten Kötting1,2, Andreas Nabers1,2, Klaus Gerwert1,2.   

Abstract

The development of biosensors for medical purposes is a growing field. An immuno-infrared biosensor for the preclinical detection of Alzheimer's disease (AD) in body fluids was developed. The key element of this sensor is an ATR crystal with chemically modified surface to catch the biomarker out of the body fluid. So far, the immuno-infrared sensor can be used only once and requires time-consuming steps of sensor exchange, sensor cleaning, and novel surface functionalization. Here, we developed an immuno-infrared sensor providing a reusable surface and showcase its performance by the detection of the AD biomarker proteins Aβ and Tau in human cerebrospinal fluid (CSF). The sensor surface is covalently coated with the immunoglobulin binding proteins Protein A or Protein G. These were employed for noncovalent immobilization of antibodies and the subsequent immobilization and analysis of their antigens. The reversible antibody immobilization can be repeated several times with the same or different antibodies. Further, the more specific binding of the antibody via its Fc region instead of the conventional NHS coupling leads to a 3-4-fold higher antigen binding capacity of the antibody. Thus, the throughput, sensitivity, and automation capacity of the immuno-infrared biosensor are significantly increased as compared to former immuno-infrared assays. This immuno-sensor can be used with any antibody that binds to Protein A or Protein G.

Entities:  

Keywords:  ATR-FTIR spectroscopy; Alzheimer’s disease; amyloid-beta and tau; biomarker detection; body fluids; immuno-infrared sensor; neurodegenerative diseases; regenerative biosensors

Mesh:

Substances:

Year:  2019        PMID: 31241315     DOI: 10.1021/acssensors.9b00631

Source DB:  PubMed          Journal:  ACS Sens        ISSN: 2379-3694            Impact factor:   7.711


  6 in total

1.  Recent Advancements in Biosensing Approaches for Screening and Diagnostic Applications.

Authors:  Andrew C Murphy; Marissa E Wechsler; Nicholas A Peppas
Journal:  Curr Opin Biomed Eng       Date:  2021-06-29

Review 2.  ATR-FTIR spectroscopy and spectroscopic imaging for the analysis of biopharmaceuticals.

Authors:  Hannah Tiernan; Bernadette Byrne; Sergei G Kazarian
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2020-06-22       Impact factor: 4.098

3.  Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.

Authors:  Julia Stockmann; Inge M W Verberk; Charlotte E Teunissen; Klaus Gerwert; Nina Timmesfeld; Robin Denz; Brian Budde; Julia Lange-Leifhelm; Philip Scheltens; Wiesje M van der Flier; Andreas Nabers
Journal:  Alzheimers Res Ther       Date:  2020-12-24       Impact factor: 6.982

4.  Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer's disease.

Authors:  Hannah Stocker; Andreas Nabers; Laura Perna; Tobias Möllers; Dan Rujescu; Annette M Hartmann; Bernd Holleczek; Ben Schöttker; Julia Stockmann; Klaus Gerwert; Hermann Brenner
Journal:  Transl Psychiatry       Date:  2021-05-01       Impact factor: 6.222

5.  ATR-FTIR Biosensors for Antibody Detection and Analysis.

Authors:  Olivier Suys; Allison Derenne; Erik Goormaghtigh
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

6.  Detection of the Chilli Leaf Curl Virus Using an Attenuated Total Reflection-Mediated Localized Surface-Plasmon-Resonance-Based Optical Platform.

Authors:  Sonatan Das; Dilip Kumar Agarwal; Bikash Mandal; V Ramgopal Rao; Tapanendu Kundu
Journal:  ACS Omega       Date:  2021-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.